ReviewExperimental and therapeutic medicine2021
Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review).
Review in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).Frontiers in immunology · 2024Trial
- Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood-Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Effects of APT20TTMG, a modulator of the U1 snRNP complex, in glioblastoma models.Medical oncology (Northwood, London, England) · 2025Article
- Navigating the Central Nervous System (CNS): A Pharmacokinetic Approach to the Treatment of CNS Tumors, Glioblastoma Multiforme (GBM), in Particular.International journal of molecular sciences · 2025Review
- Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases.International journal of molecular sciences · 2025Review
- Peimine induces apoptosis of glioblastoma cells through regulation of the PI3K/AKT signaling pathway.Experimental and therapeutic medicine · 2024Article
- Article
- Review
- High expression of BTN3A1 is associated with clinical and immunological characteristics and predicts a poor prognosis in advanced human gliomas.Frontiers in immunology · 2024Article
- POLR2J expression promotes glioblastoma malignancy by regulating oxidative stress and the STAT3 signaling pathway.American journal of cancer research · 2024Article
- Therapeutic cell-based vaccines for glioblastoma multiforme.Medical oncology (Northwood, London, England) · 2023Review
- Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics.Cancer cell international · 2023Review
- The effect of Azo-dyes on glioblastoma cellsSaudi journal of biological sciences · 2023Article
- Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells.Polymers · 2023Article
- Molecular targeted therapy: A new avenue in glioblastoma treatment.Oncology letters · 2023Review
- Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.Frontiers in immunology · 2023Article
- Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy.International journal of molecular sciences · 2022Review
- A Proteomic Platform Unveils the Brain Glycogen Phosphorylase as a Potential Therapeutic Target for Glioblastoma Multiforme.International journal of molecular sciences · 2022Article
- Glioblastoma Stem Cells-Useful Tools in the Battle against Cancer.International journal of molecular sciences · 2022Review
- Iodine Nanoparticles (NiodxPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to its localisation, rapid onset, high relapse rate and resistance to most currently available treatment methods, glioblastoma multiforme (GBM) is considered to be the deadliest type of all gliomas. Although surgical resection, chemotherapy and radiotherapy are among the therapeutic strategies used for the treatment of GBM, the survival rates achieved are not satisfactory, and there is an urgent need for novel effective therapeutic options. In addition to single-target therapy, multi-target therapies are currently under development. Furthermore, drugs are being optimised to improve their ability to cross the blood-brain barrier. In the present review, the main strategies applied for GBM treatment in terms of the most recent therapeutic agents and approaches that are currently under pre-clinical and clinical testing were discussed. In addition, the most recently reported experimental data following the testing of novel therapies, including stem cell therapy, immunotherapy, gene therapy, genomic correction and precision medicine, were reviewed, and their advantages and drawbacks were also summarised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.